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Abstract
Background: Functional deficiency of mannose-binding lectin (MBL) may contribute to the pathogenesis of
chronic obstructive pulmonary disease. We hypothesized that specific MBL2 gene polymorphisms and circulating
MBL protein levels are associated with clinically relevant outcomes in the Predicting Outcome using systemic
Markers In Severe Exacerbations of COPD PROMISE-COPD cohort.
Methods: We followed 277 patients with stable COPD GOLD stage II-IV COPD over a median period of 733
days (IQR 641–767) taking survival as the primary outcome parameter. Patients were dichotomized as frequent
(≥2 AECOPD/year) or infrequent exacerbators. Serum MBL levels and single nucleotide polymorphisms of the
MBL2 gene were assessed at baseline.
Results: The MBL2-HYPD haplotype was significantly more prevalent in frequent exacerbators (OR: 3.33; 95 %
CI, 1.24–7.14, p= 0.01). The median serum MBL concentration was similar in frequent (607 ng/ml, [IQR; 363.0–896.0 ng/ml])
and infrequent exacerbators (615 ng/ml, [IQR; 371.0–942.0 ng/ml]). Serum MBL was not associated with lung
function characteristics or bacterial colonization in sputum. However, high serum MBL at stable state was
associated with better survival compared to low MBL (p = 0.046, log rank test).
Conclusions: In COPD, the HYPD haplotype of MBL2 gene is associated with frequent exacerbations and high
serum MBL is linked to increased survival.
The PROMISE-COPD study was registered at www.controlled-trials.com under the identifier ISRCTN99586989.
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Background
The World Health Organization projects that Chronic
Obstructive Pulmonary Disease (COPD) will become the
third leading cause of death worldwide by 2030 [1]. The
increasing COPD mortality might be associated with the
aging population, tobacco use, air pollution, and respira-
tory infection [2]. In COPD patients, exacerbation causes
a mounting economic burden by frequent hospitalization
and by chronic disability. Recurrent exacerbations are
associated with accelerated lung function deterioration,
reduction of quality of life, and decreased survival in
COPD. Some COPD patients are susceptible to exacer-
bations requiring frequent hospital visits and hospitaliza-
tions. Thus, frequent exacerbation has been recognised
as a major clinically relevant COPD phenotype [3]. The
identification of predictive markers for these episodic
and recurrent worsening of symptoms may help to im-
prove the management of COPD [4].
Mannose binding lectin (MBL) is an important factor
in the innate immune system that binds to carbohydrate
regions of bacterial cell walls and viral capsules. Binding
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of MBL protein activates the complement system via
MBL-associated serine proteases, eventually leading to
the clearance of pathogens [5]. Polymorphisms of the
human MBL2 gene are associated with deficiency of
serum MBL protein levels that may cause susceptibility
to infection [4]. The polymorphisms that control the
serum MBL protein levels are located in the promoter
region, and in exon 1 of the human MBL2 gene [6]. In
general, carriers with different polymorphisms in exon 1
present low MBL serum levels. Not only that MBL2
polymorphisms and serum MBL deficiency have been
found to be associated with susceptibility to bacterial
and viral diseases, they have also been linked to non-
communicable diseases such as cystic fibrosis, and
COPD [7, 8]. Serum MBL levels for genotypes XA/O
and O/O had a mean serum level below 100 ng/ml [4].
Furthermore, COPD patients with the “O”-allele are re-
ported to suffer from recurrent infective exacerbations.
Thus, we hypothesized that specific MBL2 polymor-
phisms and circulating MBL levels are associated with
clinically relevant outcomes in COPD. To prove our hy-
pothesis, we evaluated serum MBL levels and polymor-
phisms in the MBL2 gene in a well-characterized cohort
of COPD patients.
Methods
Study population
This nested cohort study included 277 patients enrolled
in the investigator initiated PROMISE-COPD study (Pre-
dicting Outcome using systemic Markers In Severe Ex-
acerbations of COPD). The Patients were recruited at a
baseline visit after consent from 11 primary and tertiary
study centres across Europe during 2008–2011. The
study was approved by the Ethics Committee Beider Ba-
sel (EKBB 295/07), and was registered at www.con-
trolled-trials.com (ISRCTN99586989). The patients had
to be >40 years, smoking history of ≥ 10 pack years, and
be at a stable state defined as clinical stability for 4 weeks
after resolution of the last exacerbation. Patients with
pulmonary conditions other than COPD (asthma, bron-
chiectasis, cystic fibrosis), immunosuppressive diseases,
chronic steroid use >10 mg/day prednisolone-equivalent,
musculo-skeletal process preventing ambulation, and es-
timated life expectancy <6 months were excluded.
Baseline and scheduled visits assessment
COPD exacerbation was defined as an acute change
from baseline in dyspnea, cough, and/or sputum produc-
tion beyond normal day-to-day variation that necessi-
tates use of antibiotics, glucocorticoids, or both [9].
Spirometry was performed following American Thoracic
Society guidelines. Patients were categorized into COPD
stages (II-IV); (post-bronchodilator FEV1/FVC < 70 %;
FEV1 < 80 % predicted) and grouped according to the
GOLD 2011/ 2013 classification [2, 10]. Patients were
grouped into infrequent exacerbators (0–1 exacerbation/
year) and frequent exacerbators (≥2 exacerbations/year).
Outcome (all-cause mortality) was evaluated by contact-
ing the patients, family physicians, or by checking public
registries. The median follow-up time of the study was
733 days (IQR; 641–767 days). Patients answered the St.
George’s Respiratory Questionnaire (SGRQ) and the
Short Form Health Survey (SF-36) at the time of enrol-
ment. Spontaneously expectorated sputum samples were
obtained and were examined by using standard microbiol-
ogy culture techniques. Sputum samples were examined
for Gram staining. Good sputum quality was defined
as <25 epithelial cells in 100× augmentation [11].
Serum samples for MBL measurements and genotyp-
ing were collected at stable state.
Genotyping of MBL2 gene
Three single nucleotide polymorphisms (SNPs) within the
MBL2 promoter (H/L; −550, rs11003125), (X/Y; −221,
rs7096206), (P/Q; +4, rs7095891) and three SNPs in
MBL2 exon 1 (A/D; codon52, rs5030737), (A/B; codon54,
rs1800450), (A/C; codon57, rs1800451) were determined
by real-time polymerase chain reaction (RT-PCR) using
minor-groove-binder (MGB) TaqMan probes (Applied
Biosystems, Foster City, CA, USA). Genotyping was
achieved by end-point fluorescence using SDS software
(version 2.3) [12, 13]. The SNPs used to characterise the
MBL2 alleles are listed in Table 1.
Measurement of serum MBL concentration
Serum MBL was measured in duplicate by enzyme-linked
immunosorbent assay (R&D Systems, Inc., Minneapolis,
MN, USA) following the manufacturer protocol. The
serum was assigned as “low” for MBL levels below the
75th quartile (<934 ng/ml), and as “high” above the 75th
percentile (≥934 ng/ml) [14, 15].
Statistical analysis
Statistical analysis was done by SPSS (Version 21, IBM
Corp., NY, USA), and p-values less than 0.05 were con-
sidered significant. Baseline data are presented as mean
or median values (continuous variables), while discrete
data are as percentages. The association of MBL2 poly-
morphisms and low and high serum MBL, with exacer-
bation was tested by Chi-square test. The Metric data
was analysed by Students-t-test or Mann–Whitney-U
test. The Kaplan-Meier log rank test was used to test the
null hypothesis: “no difference in time to death”.
Results
Study population
Clinical characteristics of patients are summarized in
Table 2, showing a mean age of 68 years with 70 % being
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male. The majority of patients were ex-smokers with a
median cigarette consumption of 40 pack-years. The
median duration of COPD was 60 months and 185
(66.8 %) patients had exacerbations ranging from 1–15
physician visits in previous years. Of those patients,
35.9 % had a history of hospitalization in the previous
year, 9 % of which required intensive care unit stay.
GOLD classification showed that 50 % of the patients
had moderate COPD (GOLD II; 46.6 %). 123 (44.4 %)
patients were classified as frequent exacerbators.
Serum MBL levels and association with patient
characteristics
The median serum MBL level in our study cohort was
(612 ng/ml; [85–2,363 ng/ml]). There was no correlation
of serum MBL and FEV1% pred. post BD (p = 0.36). The
median serum MBL in COPD II patients was (590 ng/ml,
[IQR; 106–2106 ng/ml]), COPD III (659 ng/ml, [IQR; 94–
2,363 ng/ml]), and COPD IV (491 ng/ml, [IQR; 85–
2,120 ng/ml]). There was no difference in serum MBL
level between frequent and infrequent exacerbators (me-
dian, 612 ng/ml vs. 615 ng/ml; p = 0.59). MBL level
showed no difference between patients who died from
COPD (4.33 %) and patients who died due to other rea-
sons (6.13 %) (median, 625 ng/ml vs. 590 ng/ml; p = 0.49).
At stable state, 90 patients provided sputum of
which 26 yielded positive culture results. The isolated
organisms were: Pseudomonas aeruginosa (n = 10), En-
terobacter spp. (n = 7), Streptococcus pneumoniae (n = 6),
Haemophilus influenzae (n = 6), Moraxella catarrhalis
(n = 4), and Staphylococcus aureus (n = 1). Patients with
and without evidence of chronic bacterial colonization
had comparable circulating MBL levels (754 ng/ml;
IQR, 559–1113 ng/ml vs. 627 ng/ml; IQR, 455–
915 ng/ml, p = 0.30). Serum MBL was similar in
colonization with Gram positive vs. Gram negative
staining (762 ng/ml, [IQR 559–909 ng/ml] vs. 942 ng/ml,
[IQR, 637–1,294 ng/ml], p = 0.38).
The distribution of co-morbid state was comparable
between frequent and infrequent exacerbators and was
independent of serum MBL. A logistic regression ana-
lysis was performed to evaluate the serum MBL and its
association to patient characteristics including exacerba-
tion rate. Serum MBL was not associated with COPD
duration, age, BMI, GOLD stage, post-FEV1% predicted,
SGRQ total score, arterial hypertension, MBL2 H/L al-
lele, MBL2 exon 1 polymorphisms (A/A, vs. A/O, O/O)
(p > 0.05). In the low serum MBL group, 22 patients
(10.6 %) deceased during the study period as compared
to 2 patients (2.9 %) in the high serum MBL group. The
hazard ratio for death within 2 years for patients with high
serum MBL was 4.0 (95 % CI, 0.94–50; p = 0.05). The sur-
vival rate in patients with high serum MBL was higher
than in those with low serum MBL (Fig. 1, p = 0.046, log
rank test).
Polymorphisms in MBL2 gene
Analysing the frequency of SNPs in the MBL2 promoter
region (H/L), we observed a statistically significant differ-
ence with twenty nine (23.6 %) of the 123 frequent exacer-
bators being H/H homozygotes compared to twenty
(13.0 %) in 154 infrequent exacerbators (p = 0.043).
Similarly, the distribution of the A/D allele was sig-
nificantly different in frequent and infrequent exacer-
bators (p = 0.03). However, there was no difference in
Table 1 Mannose-binding lectin 2 (MBL2) gene polymorphisms
in patients with infrequent and frequent exacerbation
Single nucleotide
polymorphisms
Infrequent
exacerbation n (%)
Frequent
exacerbation n (%)
p value
Promoter region
HL (−550 G > C;
rs11003125)
0.03
C/C (L/L) 77 (50.0) 46 (37.4)
G/C (H/L) 57 (37.0) 48 (39.0)
G/G (H/H) 20 (13.0) 29 (23.6)
YX (−221 G > C;
rs7096206)
0.64
G/G (Y/Y) 92 (59.7) 80 (65.0)
G/C (Y/X) 53 (34.4) 36 (29.3)
C/C (X/X) 9 (5.8) 7 (5.7)
Exon 1
PQ (+4 C > T;
rs7095891)
0.65
C/C (P/P) 89 (57.8) 77 (62.6)
C/T (P/Q) 47 (30.5) 35 (28.5)
T/T (Q/Q) 18 (11.7) 11 (8.9)
A/D (+223 C > T;
rs5030737)
0.03
A/A (C/C) 124 (91.9) 119 (83.8)
A/D (C/T) 12 (7.8) 21 (17.1)
D/D (T/T) 0 (0) 1 (0.8)
A/B (+230 G > A;
rs1800450)
A/A (G/G) 129 (83.8) 106(86.2) 0.79
A/B (G/A) 23 (14.9) 15 (12.2)
B/B (A/A) 2 (1.3) 2 (1.6)
A/C (+239 G > A;
rs1800451)
A/A (G/G) 146 (94.8) 119 (96.7) 0.27
A/C (G/C) 8 (5.2) 3 (2.4)
C/C (A/A) 0 (0) 1 (0.8)
The distribution of each polymorphism in promoter and exon 1 region of
MBL2 is shown in infrequent and frequent exacerbation. The HL and AD
polymorphisms were significantly different between exacerbation groups.
The rs number for each SNP represents the reference Single nucleotide
polymorphisms identification number
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exacerbation frequency for the other allele (Y/X, P/Q,
A/B, A/C, p > 0.05 for all).
In order to test if MBL genotypes of exon 1 alleles are
associated with COPD outcomes (exacerbation fre-
quency), we grouped the genotypes into two: where the
MBL2 polymorphisms 52 (A/D), 54 (A/B), and 57 (A/C)
alleles can be grouped and referred as genotype “O” that
is considered to express low serum MBL, while the other
alleles were assigned as genotype “A” that express nor-
mal serum MBL levels [16]. In our patient cohort, the
frequency of the “O” genotype was not significantly dif-
ferent in infrequent and frequent exacerbators (27.9 %
Table 2 Demographic characteristics of study population
Total n = 277
Patient Characteristics Valuesa£
Age (years) 67.8 ± 9.5
Sex (Male) 190 (68.6)
Race (Caucasian) 274 (98.9)
BMI (kg/m2) 26.3 (23.3–29.4)
Smoking status
Current smokers, (n) % 74 (26.7)
Median Pack-years, median, IQR 50 (35–80)
Comorbidities
Congestive heart disease, % 17.5
Diabetes mellitus, % 12.9
Liver disease, % 2.9
Malignant solid tumour, % 4.0
Arterial hypertension, % 56.4
Pulmonary arterial hypertension, % 8.0
History of exacerbations in COPD
patients in previous years
Median duration of COPD (months),
median IQR
84 (44.5–130)
Duration of physician-diagnosed COPD
(months), median, IQR
60 (29–120)
Required unscheduled urgent physician
visit, median, IQR
1 (0–2)
Required hospitalization, median, IQR 0 (0–1)
Antibiotics use, median, IQR 1 (0–1)
Current medication for COPD
SABA + SAMA, % 20.6
LABA + ICS, % 73.5
Single drug inhaler
SABA, % 31.4
LABA, % 12.27
SAMA, % 6.2
LAMA, % 71.7
ICS, % 11.7
Lung function tests
FEV1,L post-BD, mean ± S.D. 1.4 ± 0.6
FEV1 % predicted post-BD, mean ± S.D. 48.2 ± 17.5
FVC,L post-BD, mean ± S.D. 2.9 ± 3.8
FVC % predicted post-BD, mean ± S.D. 77.9 ± 23.2
FEV1/FVC post-BD, mean ± S.D. 48.0 ± 13.6
GOLD Stages
GOLD II, (n) % 129 (47.3)
GOLD III, (n) % 104 (38.1)
GOLD IV, (n) % 40 (14.6)
SGRQ - Quality of life
Symptoms score, median IQR 46.3 (29.3–65.8)
Table 2 Demographic characteristics of study population
(Continued)
Activity score, median IQR 59.4 (42.4–79.2)
Impact score, median IQR 30.0 (18.3–46.5)
Total score, median IQR 41.8 (29.5–57.8)
SF-36 Health Survey
Physical Function, median IQR 50.0 (25.0–70.0)
Role Function, median IQR 50.0 (0.0–100.0)
Role Emotional, median IQR 100.0 (8.3–100.0)
Social Function, median IQR 75.0 (50.0–100.0)
Mental Health, median IQR 65.0 (55.0–80.0)
Body Pain, median IQR 74.0 (51.0–100.0)
Vitality, median IQR 50.0 (37.5–62.5)
General Health, median IQR 45.0 (28.3–65.0)
Exercise performance
6MWD, m, mean ± S.D. 375.5 ± 102.6
Peripheral Oxygen saturation at rest,
mean ± S.D.
94.5 ± 2.7
Lowest oxygen saturation during test,
mean ± S.D.
89.6 ± 6.0
Heart rate at rest (beats/min), mean ± S.D. 80.8 ± 14.7
Highest heart rate during test (beats/min),
mean ± S.D.
105.9 ± 19.49
6 min’ walk BORG score, median IQR 4 (3–6)
BODE index, median IQR 3 (1–4)
Serum MBL level
Serum MBL concentration, ng/ml,
median, IQR
612 (365.5–933.0)
Low serum MBL level (<75th quartile;
<934 ng/ml), (n) %
208 (75.1)
High serum MBL level (≥75th percentile;
≥934 ng/ml), (n) %
69 (24.9)
aThe continuous data are presented as mean ± SD or median (IQR). £The count
data is presented as No. (%). GOLD Global initiative for chronic obstructive
lung disease, COPD Chronic obstructive pulmonary disease, ICS Inhaled
corticosteroids, LABA Long-acting beta2-agonist, LAMA Long-acting muscarinic
antagonists, SGRQ St. George’s respiratory questionnaire, 6MWD 6 min walking
distance, MBL Mannose binding lectin, SABA Short-acting beta2-agonist, SAMA
Short-acting muscarinic antagonists, SF-36 Short form (36) health survey
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vs. 31.7 %; p = 0.47), and, the serum MBL level was inde-
pendent of exon 1 alleles (p = 0.39).
In a second approach, we combined the promoter X/Y
allele with the pooled exon 1 A/O alleles which is con-
sidered to change serum MBL level [17]. In our cohort,
the XA/XA and YO/YO genotypes were the least fre-
quent, however the distribution of all possible six geno-
types was not different between frequent and infrequent
exacerbators (p > 0.05, for all), and no association with
serum MBL was observed (p > 0.05) (Additional file 1:
Table S1).
Frequencies of MBL2 haplotypes and serum MBL
The MBL2 haplotype frequency in infrequent and fre-
quent exacerbators is summarized in Table 3. To further
investigate the serum MBL and its function, we com-
pared the MBL haplotypes to serum MBL concentration
and patient’s characteristics. Haplotypes (LYPB, HYPD,
and LYQC) that code for low serum MBL were less fre-
quent represented by 15.6 % of the cohort. Based on an
earlier report we categorized the MBL2 polymorphisms
as: “high”, “intermediate”, and “low” serum MBL concen-
tration expressing genotypes [18–21], and compared it
to exacerbation frequency [15]. However, in this cohort
neither the exacerbation frequency nor the serum MBL
was different across “MBL concentration genotypes”.
Similar median values of serum MBL were observed in
infrequent exacerbators (614.5 ng/ml; IQR, 371.0–
942.0 ng/ml), and frequent exacerbators (607.0 ng/ml;
IQR, 363.0–896.0 ng/ml; p = 0.91). Patients with the
HYPD haplotype had similar hospitalization history, risk
to congestive heart failure, arterial hypertension, and
death rate (p > 0.05) compared to all other haplotypes.
However, we found significantly more HYPD haplotype
carriers among the frequent exacerbators (p = 0.01)
(Table 3).
Fig. 1 Kaplan-Meier survival analysis of patients with low and high serum MBL levels in COPD patients. The survival analysis of time to death
showed significant survival advantage among patients with high serum MBL levels as compared to those with low serum MBL levels (Log rank,
p = 0.046). MBL = Mannose binding lectin
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Discussion
In this study, we present three important new findings.
Firstly, we found that significantly more HYPD haplotype
carriers, supposed to express low serum MBL levels, were
frequent exacerbators. Secondly, serum MBL was neither
predictive for COPD severity, exacerbation frequency, nor
for bacterial colonization. And finally, low serum MBL at
stable state was associated with reduced survival. To our
knowledge this is the largest and most comprehensive
study assessing both serum MBL and MBL2 haplotypes in
Caucasians COPD patients.
It has been argued that COPD exacerbation involves
the innate immune response, which is linked to serum
MBL, and MBL2 gene polymorphisms [3, 22]. The
MBL2 genotypes result from several polymorphisms in
both the promoter and exon 1 region and are assumed
to modify serum MBL levels [15, 23]. The promoter al-
lele X/Y was linked with pooled exon 1 (A/A, A/O, O/O)
polymorphisms to form genotypes (e.g. YA/YA, XA/YO),
which account for increased serum MBL. It has been
suggested that the promoter X allele causes low expres-
sion of MBL, while any polymorphisms in exon 1 were
associated with reduced MBL function in Caucasians [24].
Previous studies showed that the most commonly de-
scribed MBL2 haplotypes (HYPA, LYPA, LXPA, LYQA,
HYPD, LYPB, LYQC) predict susceptibility to various dis-
eases [25–27]. In this COPD cohort we describe for the
first time a significant difference for the allele frequency of
H/L and A/D in frequent and infrequent exacerbators.
The high frequency of the HYPA (31 %) haplotype was
expected, as it is the most common haplotype among
Europeans. However, the LYPB (8 %) haplotype was less
frequent than described elsewhere [28], but was signifi-
cantly increased in frequent exacerbators. Previous stud-
ies found the HYPD haplotype to modulate the risk for
liver disease in cystic fibrosis [27, 29], while it was pro-
tective against pulmonary tuberculosis [25]. Our data
proposes the HYPD haplotype as a marker of frequent
exacerbation in COPD, while it was not linked to serum
MBL levels. It is indicated that serum MBL <100 ng/ml
present a deficiency and occurs in 5 % Europeans [30].
In contrast, only 2 (0.7 %) patients in our cohort pre-
sented serum MBL <100 ng/ml. Since only MBL suffi-
cient genotypes responded to acute phase reactivity in
pneumonia, serum MBL may not significantly increase
in patients with MBL deficiency genotypes despite in-
flammation [31].
In cystic fibrosis, MBL2 levels correlated with reduced
FEV1 % predicted [32]. Conversely, in COPD patients at
stable state, we found only a trend for a correlation of
serum MBL and FEV1% predicted. Herein, the additional
lack of association of serum MBL with other COPD pa-
rameters such as quality of life, BODE index, exercise
capacity, or duration of symptoms supports the notion
that serum MBL does not directly relate to the severity
of the disease in COPD. It has been reported earlier that
MBL deficiency showed no association to COPD severity
[33]. Studies have shown that MBL deficiency may have
detrimental consequences on the long-term outcomes in
chronic granulomatous disease (CGD) [34] and those
with variant forms of MBL have a high risk of develop-
ing autoimmune disorders [35].
In other diseases, such as cystic fibrosis, it was re-
ported that MBL2 deficiency was associated to infection
with Pseudomonas aeruginosa and Burkholderia cepacia
[32]. However, in our study, circulating MBL levels in
patients with and without bacterial colonisation were
similar. Specifically, colonization by Pseudomonas aeru-
ginosa was not associated with lower circulating MBL
levels. Therefore, the association of MBL deficiency and
Pseudomonas aeruginosa may be disease specific. [32],
Regarding the link of MBL alleles and infection suscepti-
bility we found no difference between patients with and
without colonization and serum MBL levels, while it was
suggested that Y/Y promoter homozygotes are more sus-
ceptible to bacterial colonization [36]. MBL2 polymor-
phisms had been presented to increase the risk of
pneumonia and low serum MBL was controversially cor-
related with an increased risk of bacterial and viral infec-
tions [31]. Furthermore, a large study in Caucasian
Table 3 Frequency of MBL2 haplotypes in relation to exacerbations
MBL2 Haplotype Expected serum MBL Level Infrequent exacerbation Frequent exacerbation p value
n Frequency n Frequency
HYPA High 87 0.282 85 0.346 0.13
LYQA High 75 0.243 53 0.215 0.49
LYPA High 30 0.097 15 0.061 0.16
LXPA Intermediate 71 0.230 50 0.203 0.50
LYPB Low 27 0.087 19 0.077 0.77
HYPD Low 10 0.032 21 0.085 0.01
LYQC Low 8 0.026 3 0.012 0.39
The distribution of haplotypes corresponding to express high to low serum MBL are categorized in infrequent and frequent exacerbation. Here, the HYPD
haplotype is significantly higher among frequent exacerbators
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showed no association of exon 1 MBL2 genotypes and
infection [37]. Bacterial surface lipopolysaccharide cap-
sular antigen of Streptococcus pneumoniae causes airway
inflammation, stimulating and binding with MBL protein
and potentially leading to exacerbations [38]. Another
study found the high-MBL expressing HYPA haplotype
more frequent among controls than in patients with in-
fection [39]. In isolates from immune-compromised chil-
dren, MBL protein bound only to a selection of bacteria
[40]. Most of these strong MBL binding bacteria were
not encountered in the present COPD cohort suggesting
a limited involvement in innate immunity. Yang et al.
described a significant association between the MBL2-54
A/B allele and reduced serum MBL with infective COPD
exacerbation. Unfortunately, exacerbations were not fur-
ther differentiated for microorganisms [41]. In the
present cohort, we observed a better survival in patients
with high MBL levels. In accordance with our findings,
Dahl et al. reported a higher prevalence of cardiovascu-
lar disorders in deficient MBL2 carrier patients [37]. In
kidney transplant patients, the low serum MBL haplo-
types XA and YO were also significantly associated with
reduced survival [42]. These results are in agreement
with a study in the United Kingdom showing that lower
circulating MBL level was related to poor disease out-
come in septic shock [43]. Although this study lacks the
ability to define precise mechanisms of the role of serum
MBL to disease pathogenesis, our findings suggest that
high serum MBL is protective in COPD.
We have observed that increased MBL levels corre-
lated with increased survival, Shall its protective effect
be confirmed in further studies, it would be worthwhile
exploring recombinant or purified MBL replacement as
a therapeutic strategy in high-risk patients with COPD.
Limitations
The limitations of this study are: we did not have a con-
trol group, which would have added value to this ana-
lysis. However, the distribution of MBL2 polymorphisms
in our population was similar to that reported in the
dbSNP database [44]. We cannot exclude the possibility
that an association between deficient MBL2 genotypes
and serum MBL concentrations could be evidenced in a
population with a different ethnic background and/or
larger sample size. There is no consensus in defining defi-
cient serum MBL levels, thus we used the 4th quartile as
threshold value. As any data driven definition, this thresh-
old might overestimate any association. Taking in to ac-
count that MBL might exert a local effect in the lung,
which is not reflected in the serum, it would be of interest
to compare serum to BAL samples. However in the setting
of this study BAL samples were not collected. The range
of MBL in BAL samples is at least 100 times greater than
what we observed in serum samples (ng/ml vs pg/ml).
Therefore the variation in our samples is significantly
smaller as compared to that of Hodge et al. [45]. It would
be of interest to determine the influence of MASP2 with
MBL2 as only the complex of both proteins exerts an
anti-bacterial/viral effect. However, to include this data in
our cohort we would also have to determine all known
polymorphisms for MASP2 and then combine them with
all genotypes of MBL2. Similarly, the association between
HYPD haplotype and frequent exacerbations should be
confirmed in further studies. Nevertheless, the major
strength of this study is the detailed patient and disease
activity characterisation of a pan-European COPD cohort.
Conclusions
The major findings of this study suggests that Caucasian
COPD patients with the MBL2-HYPD haplotype demon-
strate more commonly frequent exacerbations, while
high serum MBL at stable state is associated with in-
creased survival.
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